ABSTRACT
Background:In this study, we aimed to evaluate the response of patient treated with omalizumab at certain time intervals through 6 months with pruritus visual analog scale, urticaria activity score and quality of life indexes. Methods:The study was performed on ten patients diagnosed with chronic idiopathic spontaneous urticaria.The disease was assessed by the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) and Dermatology Life Quality Index(DLQI) for every 2 weeks while was assessed by Urticaria Activity Score (UAS-7) and Pruritus Visual Analog Scale (PVAS) for once a week during the 6-month treatment period.Statistical significance was evaluated using the Mann-WhitneyUtest in SPSS 20.Results:Pre-treatment values of the DLQI, CU-Q2oL, UAS-7, and PVAS was statistically higher than post-treatment values of these indexes (p<0.05). The mean DLQI/ CU-Q2oLvalue of the patients beforetreatment was 17±6.09/ 52.87±22.07 while it was 19.4±16.36 at the end of 2nd-week post-injection per month, and was 21.85±16.56 at the end of 4nd-week post-injection per month during 6-months following. Statistically, PVAS score at the 4thweek was higher than 2nd and 3rdweeks(p<0.042, p<0.007).Conclusions:In this study, it was detected that omalizumab had a significant effect on DLQI, CU-Q2oL, UAS-7, PVAS scores in CISU. It can be concluded that significant increase of PVAS score at 4th week compared to scores at 2nd and 3rd week may necessitate the use of omalizumab combined with antihistamines at 4th week of the treatment
ABSTRACT
We report a patient with severe acne who developed facial paralysis after two months of treatment with oral isotretinoin. Drug withdrawal resulted in a complete clinical recovery. Our case and a review of the literature indicate that oral isotretinoin might be capable of causing a dysfunction of predominantly sensory nerve fibers in some individuals. Clinicians should be aware of possible neurological sensorial symptoms during isotretinoin therapy